Read this recently published Journal of Chemistry paper discussing how WuXi STA scientists and their partner AstraZenaca collaborated to improve the process for a synthetically challenging atropisomeric KRASG12C inhibitor resulting in a reduced step count and streamlined protecting group strategy to support efficient clinical API manufacture.
Menu
CONNECT WITH US
